Mr. Doug Drysdale reports

CYBIN INC. ANNOUNCES APPOINTMENT OF AARON BARTLONE AS CHIEF OPERATING OFFICER

Cybin Inc. has appointed Aaron Bartlone as chief operating officer, effective July 1, 2023. Mr. Bartlone has served as chief operating officer of Cybin's U.S. subsidiary, Cybin U.S. Holdings Inc., since March, 2021.

With 30 years of experience in the biopharmaceutical industry, Mr. Bartlone has a record of driving novel therapeutics through clinical development into global markets, with significant expertise in the areas of product development, commercial operations, quality assurance and regulatory affairs. Previously, Mr. Bartlone held roles of increasing responsibility, including commercial president and chief quality, patient safety, health, safety and environment, and risk officer at UCB Inc., a global biopharmaceutical company. Mr. Bartlone has driven over 25 small and large molecular therapies and drug-device combination products to the global marketplace, and has developed global teams of over 1,000 colleagues in 50 countries. Mr. Bartlone has also held various director-level product development, quality, regulatory and managerial positions at Eli Lilly. Mr. Bartlone has a bachelor of science in chemistry from Youngstown State University and a master of science in analytical chemistry from the University of Notre Dame.

"Aaron's leadership and expertise have contributed immensely to Cybin's clinical accomplishments across its drug development programs, including progressing the ongoing phase 1/2a study of CYB003, and the phase 1 CYB004-E study. Aaron's significant experience in regulatory, commercial and clinical operations will continue to be an asset as Cybin advances its programs," said Doug Drysdale, chief executive officer of Cybin. "We are pleased to appoint Aaron as chief operating officer of Cybin Inc. and view this as a key step in strengthening the company's execution as we continue to advance our clinical trials towards data readouts later this year."

"Cybin has established a leadership position as a developer of new and differentiated therapeutics for mental health conditions," said Mr. Bartlone. "I look forward to continuing to support Cybin's mission of bringing these improved treatment options to patients in need."

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin's goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analogue for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds.

Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

We seek Safe Harbor.